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INTRODUCTION 
 
        Non-alcoholic steato hepatitis (NASH) is a subset of non-alcoholic fatty 
liver disease (NAFLD). It is a disorder currently characterized by a 
constellation of histological abnormalities identified on liver biopsy that are 
similar to those seen in alcoholic liver disease but in patients who consume 
little or no alcohol. The prevalence of NASH is increasing in parallel with 
dramatic increases in obesity, sedentary life style and Type II Diabetes 
Mellitus. 
         Diabetes is a common metabolic disorder that affects a large number of 
people worldwide, the diabetic population is ever growing and it has now 
reached enormous proportions. Diabetes mellitus affects almost all systems 
in the body and it causes considerable morbidity and mortality. Diabetes 
mellitus, hyperlipidemia and obesity have been implicated as potential 
causes for the development of NAFLD and now newer risk factors have 
been proposed. 
          A plethora of case series of NAFLD  have been reported over the past 
few years but whether this indicates a true increase in prevalence or simply an 
increased awareness of this disorder is unclear. 
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          Stanley Medical College is located in Chennai and caters to the 
medical needs of a large diabetic population. Many cases of Diabetes 
mellitus also have chronic liver disease; some of them do not have a history 
of significant alcohol consumption, so we thought that these cases might 
represent a sample of what is called cryptogenic cirrhosis. 
           A significant proportion of patients previously thought to have 
cryptogenic cirrhosis share many of the clinical and demographic features of 
nonalcoholic fatty liver disease, suggesting that the etiology of their cirrhosis 
may be unrecognized NAFLD. 
        So we conducted this study to evaluate the prevalence and general 
characteristics of Non alcoholic Fatty Liver Disease in type II diabetics with 
a motive to provide some information that might be useful for future 
reference and to evaluate the impact of this disease on persons belonging to 
this geographical region. 
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AIM OF THIS STUDY 
                        
1. To find out the Prevalence and General characteristics of Non 
Alcoholic Fatty Liver Disease in persons with Type 2 Diabetes Mellitus 
attending outpatient clinic in Stanley Medical College. 
2. To assess the different clinical presentations of Non Alcoholic Fatty 
Liver Disease in Type 2 Diabetes Mellitus patients. 
3. To assess the relationship between Body Mass Index and Non 
Alcoholic Liver Disease in Type 2 Diabetes Mellitus. 
4. To correlate the results of Liver Function Tests with Ultrasonographic 
evidence of fatty liver in Type 2 Diabetes Mellitus. 
5. To correlate the results of fasting Lipid Profile with Ultrasonographic 
evidence of fatty liver in Type 2 Diabetes Mellitus. 
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REVIEW OF LITERATURE 
The liver plays a pivotal role in the metabolism of carbohydrates and lipids; 
affection of liver is common in diabetes. Sometimes liver disease may give 
rise to abnormalities in glucose homeostasis, and finally certain diseases of 
liver might be present coincidentally with diabetes.1 
LIVER DISEASE IN DIABETES MELLITUS 
1. Liver disease occurring as a consequence of diabetes mellitus 
• Glycogen deposition 
• Steatosis and nonalcoholic steatohepatitis(NASH) 
• Fibrosis and cirrhosis 
• Biliary disease, cholelithiasis, cholecystitis 
• Complications of therapy of diabetes (cholestatic and 
necroinflammatory) 
2. Abnormalities of glucose homeostasis occurring as a complication of 
liver disease can be present in 
• Hepatitis 
• Cirrhosis 
• Hepatocellular carcinoma 
• Fulminant hepatic failure 
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3. Liver disease occurring coincidentally with diabetes mellitus and 
abnormalities of glucose homeostasis. 
• Hemochromatosis 
• Glycogen storage diseases 
• Autoimmune biliary disease 
 
      Hepatic fat accumulation is a well recognized complication of diabetes 
with a reported frequency of 40 – 70 %. Unfortunately, associated obesity is 
frequently occurring confounding variable.  Type I diabetes is not associated 
with fat accumulation if glycemia is well controlled, but type 2 diabetes may 
have a 70 % correlation regardless of blood glucose control.1 
HISTORICAL ASPECTS 
       Jurgen Ludwig, a Mayo Clinic pathologist, popularized the term “Non 
alcoholic steatohepatitis” in a paper published in 1980.2 
        In 1952 Zelman described liver biopsy findings in 19 obese men that 
included steatosis and varying degrees of inflammation and fibrosis.3  
       These early studies set the stage for the Ludwig series that convinced 
many in the field that NASH was a potentially serious disorder that was truly 
unrelated to alcohol consumption and could no longer be ignored. 
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NOMENCLATURE 
        Nonalcoholic fatty liver disease refers to a broad spectrum of liver 
disease ranging from steatosis (bland fatty infiltration of hepatocytes) to 
nonalcoholic steatohepatitis (steatosis plus inflammation, necrosis or 
fibrosis) to cirrhosis and, in some patients, to end-stage liver disease and 
hepatocellular carcinoma. These facts have been in documented in studies 
done by Lee R .G et al (1989)4 and Powell E .E et al 5(1990). 
EPIDEMIOLOGY 
RISK FACTORS FOR NAFLD 
            The most common underlying risk factor for the development of 
NASH is the presence of insulin resistance. NASH is found to occur 
equally in both genders. Hyperlipidemia, typically hypertriglyceridemia is 
associated with NAFLD.6-12 
CONDITIONS ASSOCIATED WITH NAFLD 6-12 
INSULIN RESISTANCE 
• Obesity 
• Sedentary lifestyle 
• Type 2 diabetes 
• Hypertriglyceridemia 
• Hypertension 
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DRUGS 
• Tamoxifen 
• Corticosteroids 
• Amiodarone 
• Estrogens 
• Calcium-channel blockers 
TOXINS 
• Extensive exposure to volatile hydrocarbons 
DIETARY ABNORMALITIES 
• Carbohydrate excess (e.g., dietary, total parenteral nutritional) 
• Protein deficiency 
• Rapid weight loss 
• Vitamin B12 deficiency 
ALTERED SMALL ANATOMY 
• Obesity surgery with blind loop of small bowel 
• Small bowel diverticula 
• Short gut 
METABOLIC DISEASES (RESULTING IN NASH-LIKE 
HISTOLOGY) 
• Hyperbetalipoproteinemis 
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• Abetalipoproteinemia 
• Wilson’s disease 
• Lipodystrophies 
• Andersen’s disease  
• Weber-Christian syndrome 
• Mauriac syndrome 
INFECTIONS 
• Chronic hepatitis C ( usually genotype 3) 
• AIDS 
• Bacillus cereus infection 
PREVALENCE OF NAFLD IN ADULTS 
            The best estimates based on currently available data indicate that 
about 20 % of adults in the USA have Non-Alcoholic Fatty Liver 
Disease(NAFLD) and about 2-3 % of all adults have Non-Alcoholic Steato- 
Hepatitis(NASH).13, 14 
                        NAFLD(including NASH)  :   20 % 
                        NASH                                    :   3-4 % 
                        NASH with fibrosis              :   1 % 
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PREVALENCE OF NAFLD IN CHILDREN 
               The full spectrum of NAFLD is found in children.15 One study in 
Japan of 810 children aged 4-12 years old demonstrated the presence of 
sonographically detectable NAFLD in 2-6 % and its presence correlated 
with obesity.16 
 
 
 
PROGRESSION OF NAFLD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Two thirds of adults                 
          are overweight or 
          Obese; 70 % are 
           Sedentary 
 
 
                                             
        
 
 
          20 % of adults have 
             NAFLD; 3-4 %  
             Have NASH                                                                                         
Obesity 
Sedentary 
lifestyle 
Genetics
INSULIN RESISTANCE
Type 2 DM 
Hypertension 
Hyperlipidemia
Steatosis with 
Necroinflammatory 
Changes (NASH) 
Steatosis alone 
Progressive fibrosis 
In some patients 
CIRRHOSIS 
(“CRYPTOG
ENIC”) 
HCC LIVER TRANSPLANT 
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CLINICAL MANIFESTATIONS 
CLINICAL FEATURES 
           NAFLD is usually asymptomatic14, although fatigue and discomfort 
in the right upper quadrant of the abdomen may be reported.17  The majority 
(56%-79%) of patients are overweight (body mass index [BMI] >25 kg/m2), 
and one-third have metabolic syndrome.18,19,20  Lean patients (BMI 25 
kg/m2) usually have at least one metabolic risk factor. Hepatomegaly may be 
present, although signs of chronic liver disease are uncommon.17, 21 
           Hepatomegaly is the only physical finding in most patients. 
Acanthosis nigricans may be found in children with nonalcoholic fatty liver 
disease.18, 22 Findings of chronic liver disease and diminished number of 
platelets suggest that advanced disease with cirrhosis is present. A high 
proportion of patients with cryptogenic cirrhosis share many of the clinical 
and demographic features of patients with nonalcoholic fatty liver disease, 23 
suggesting that their cryptogenic cirrhosis is unrecognized nonalcoholic fatty 
liver disease. 
             Common symptoms and signs of 400 subjects with NAFLD (Data 
from the NAFLD clinic at Virginia Commonwealth University, previously 
unpublished data).24  
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Symptoms and signs NAFLD
(N=75) 
% 
 
NASH 
(N=325)
% 
Asymptomatic 60 55 
Fatigue 30 45 
Pruritis 2 4 
Rt. upper quadrant discomfort 30 32 
Edema 4 5 
hepatomegaly 22 28 
Stigmata of chronic liver disease 8 10 
Diabetes 45 50 
Hypertension 60 65 
Obesity 65 60 
 
LABORATORY ABNORMALITIES 
 
          Mildly to moderately elevated serum levels of aspartate 
aminotransferase, alanine aminotransferase, or both are the most common 
and often the only laboratory abnormality found in patients with 
nonalcoholic fatty liver disease. The ratio of aspartate aminotransferase to 
alanine aminotransferase is usually less than 1, but this ratio increases as 
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fibrosis advances, leading to a loss of its diagnostic accuracy in patients with 
cirrhotic nonalcoholic fatty liver disease.25 Serum alkaline phosphatase, 
gamma glutamyltransferase, or both are above the normal range in many 
patients, although their degree of elevation is less than seen in alcoholic 
hepatitis. An ALT or AST value >300 IU/L should raise the suspicion of 
alternate pathology.26 The degree of abnormality is usually moderate and 
does not exceed 2-3 times the upper limit of normal values. Unfortunately, 
none of these tests are sensitive or specific enough to establish a diagnosis of 
NAFLD with great accuracy. 
        Other abnormalities including hypoalbuminemia, a prolonged 
prolonged prothrombin time, and hyperbilirubinemias, may be found in 
patients with cirrhotic stage nonalcoholic fatty liver disease. 
          Ferritin levels are increased in 20%-50% of patients, and elevated 
transferring saturation (>55%) is present in 5-10%.27 
          Autoantibodies are identified in 23%-36% of NAFLD patients and are 
associated with more advanced fibrosis.28, 29 
          However, in studies of subjects with persistently elevated ALT values 
without an obvious explanation, NAFLD was found in only 70-80% of cases 
and 20-30% of subjects were found to have an alternate cause for their 
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elevated liver enzymes.30 Of note, 5-9% of subjects had a normal liver 
despite a complete evaluation. 
IMAGING STUDIES 
         On Ultrasonography, fatty infiltration of the liver produces a diffuse 
increase in echogenicity as compared with that of the kidneys. Regardless of 
the cause, cirrhosis has a similar appearance on ultrasonography. 
Ultrasonography has a sensitivity of 89 percent and a specificity of 93 
percent in detecting steatosis and a sensitivity and specificity of 77 
percent and 89 percent, respectively, in detecting increased fibrosis.31 
Fatty infiltration of the liver produces a low-density hepatic parenchyma on 
Computed Tomographic (CT) scanning. Steatosis is diffuse in most patients 
with nonalcoholic fatty liver disease, but occasionally, it is focal. 
Sonography of fatty liver may be varied depending on the amount of fat and 
whether deposits are diffuse or focal.32 
Diffuse steatosis may be: 33 
Mild:     minimal diffuse increase in hepatic echogenicity; normal 
visualization of diaphragm and intrahepatic vessel borders. 
Moderate:    moderate increase in hepatic echogenicity; slightly impaired 
visualization of intrahepatic vessels and diaphragm. 
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Severe:  marked increase in echogenicity; poor penetration of the posterior 
segment of right lobe of liver and poor or non-visualization of the hepatic 
vessels and diaphragm. 
Sonographic features of focal fatty changes are: 
           Focal fat may show rapid change with time both in appearance and 
resolution, it does not alter the course or caliber of regional blood vessels 
and does not produce contour abnormalities, and the preferred site for both 
focal fat deposition and focal sparing is the area anterior to the portal vein at 
the porta hepatis. Sometimes focal fat may produce geographic map-like 
boundaries. 
          CT imaging of the liver produces a more sensitive method for the 
non-invasive diagnosis of NAFLD. Hepatic steatosis decreases the CT 
attenuation of the liver. When the hepatic parenchymal attenuation is 10 or 
more Houndsfield units lower than the spleen on a non-contrast-enhanced 
scan, a diagnosis of hepatic steatosis can be made. When intravenous 
contrast is administered, the hepatic enhancement lags behind the spleen and 
the liver-to-spleen attenuation differential exceeds 20 Houndsfield units. 
These features allow hepatic steatosis to be defined with a 76% positive 
predictive value.34 
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           Magnetic resonance spectroscopy allows a quantitative assessment of 
fatty infiltration of the liver, 35 and a minimum of 5%-10% steatosis by 
weight is considered a requirement for the diagnosis of NAFLD.  
       The sensitivity of each imaging method increases with the degree of 
fatty infiltration, with at least 33% steatosis  being optimal for detection.34 
        The combination of steatosis, infiltration by mononuclear cells or 
polymorphonuclear cells (or both), and hepatocyte ballooning and spotty 
necrosis is known as nonalcoholic steatohepatitis. Most patients with this 
type of non alcoholic fatty liver disease have some degree of fibrosis, 
whereas Mallory’s hyaline may or may not be present. The severity of 
steatosis can be graded on the basis of the extent of involved parenchyma.36 
A system that unifies the lesions of steatosis and necroinflammation into a 
“grade” and those of the types of fibrosis into a “stage” has been recently 
proposed.36 
PATHOGENESIS37 
      The pathogenesis of nonalcoholic fatty liver diseases has remained 
poorly understood since the earliest description of the disease. Much current 
thinking remains hypothetical, since the mechanism or mechanisms are still 
being worked out. It is not yet understood why simple steatosis develops in 
some patients, whereas steatohepatitis and progressive disease develop in 
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others; differences in body-fat distribution or antioxidant systems, possibly 
in the context of a genetic predisposition, may be among the explanations. 
       A net retention of lipids within hepatocytes, mostly in the form of 
triglycerides, is a prerequisite for the development of nonalcoholic fatty 
liver disease.  
              Insulin resistance (owing to inhibition of tumor necrosis factor α 
[TNF- α], Rad, PC-1, eptin, and fatty acids) leads to the accumulation of 
fat in hepatocytes by two main mechanisms: lipolysis, which increases 
circulating fatty acids, and hyperinsulinemia. Increased uptake of fatty 
acids by hepatocytes leads to mitochondrial β-oxidation overload, with the 
consequent accumulation of fatty acids within hepatocytes. Fatty acids are 
substrates and inducers of the microsomal lipoxygenases cytochrome P-450 
2E1 and 4A.38,39 The level of cytochrome P-450 2E1 is invariably increased 
in the liver of patients with steatohepatitis and may result in the production 
of free oxygen radicals capable of inducing lipid peroxidation of hepatocyte 
membranes.38 Hyperinsulinemia resulting from insulin resistance increases 
the synthesis of fatty acids in hepatocytes by increasing glycolysis and 
favors the accumulation of triglycerides within hepatocytes by decreasing 
hepatic production of apolipoprotein B-100.  
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        Micrososmal ω-oxidation of fatty acids generates dicarboxylic fatty 
acids, which are further degraded by peroxisomal β-oxidation. Peroxisomal 
β-oxidation generates chain-shortened acyl-coenzyme A. Very-long-chain 
fatty acids are converted to acyl-coenzyme A by the action of acyl-
coenzyme A synthetase. Acyl-coenzyme A serves as a substrate for 
peroxisomal oxidation, but if left unmetabolized, it functions as a PPAR- α 
ligand. PPAR- α controls the induction of genes involved in microsomal, 
peroxisomal, and mitochondrial fatty-acid systems in liver, and it may also 
promote hepatic synthesis of uncoupling protein-2. The role of this protein 
in the pathogenesis of nonalcoholic fatty liver disease remains uncertain. It 
may help inhibit hepatocyte apoptosis, but it may also increase the 
vulnerability of fatty hepatocytes to subsequent injury when exposed to 
secondary insults such as endotoxin or TNF- α.40, 41 
 
         Mitochondrial reactive oxygen species promote progression from 
steatosis to steatohepatitis42, 43 and fibrosis by three main mechanisms: 
lipid peroxidation, cytokine induction, and Fas ligand induction. Reactive 
oxygen species trigger lipid peroxidation, which causes cell death and 
releases malondialdehyde (MDA) and 4-hydrxynonenal (HNE). MDA and 
HNE cause cell death; cross-link proteins, leading to the formation of 
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Mallory’s hyaline; and activate stellate cells, promoting collagen synthesis. 
HNE has chemotactic activity for neutrophils, promoting tissue 
inflammation. Reactive oxygen species also induce the formation of the 
cytokines TNF- α, transforming growth factor β (TGF- β), and interleukin-8. 
TNF- α and TGF- β cause caspase activation and hepatocyte death. TGF- β 
activates collagen synthesis by stellate cells and activates tissue 
transglutaminase, which cross-links cytoskeletal proteins, promoting the 
formation of Mallory’s hyaline. Interleukin-8 is a potent chemoattractant for 
human neutrophils. The TNF- α induced by reactive oxygen species further 
impairs the flow of electrons along the respiratory chain in mitochondria. 
Mitochondrial reactive oxygen species can deplete hepatic antioxidants, 
allowing accumulation of more reactive oxygen species.42, 43 Mitochondrial 
reactive oxygen species cause expression of the Fas ligand in hepatocytes, 
which normally express the membrane receptor Fas. The Fas ligand on one 
hepatocyte can then interact with Fas on another hepatocyte, causing 
fractional killing. 
       Insulin resistance is the most reproducible factor in the development of 
nonalcoholic fatty liver disease.44, 45 The molecular pathogenesis of insulin 
resistance seems to be multifactorial, and several molecular targets involved 
in the inhibition of insulin action have been identified. Insulin resistance 
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leads to fat accumulation in hepatocytes by two main mechanisms; 
lipolysis and hyperinsulinemia.  
         Clinically significant amounts of dicarboxylic acids, which are 
potentially cytotoxic, can be formed by microsomal ω-oxidation. This 
pathway of fatty acid metabolism is closely related to mitochondrial β-
oxidation and peroxisomal β-oxidation. Deficiency of the enzymes of 
peroxisomal β-oxidation has been recognized as an important cause of 
microvesicular steatosis and steatohepatitis.40 Deficiency of acyl-coenzyme 
A oxidase disrupts the oxidation of very-long-chain fatty acids and 
dicarboxylic acids, leading to extensive microvesicular steatosis and 
steatohepatitis. Loss of this enzyme also causes sustained hyperactivation of  
peroxisome-proliferator-activator receptor α (PPAR- α), leading to 
transcriptional up-regulation of PPAR- α-regulated genes. PPAR- α has been 
implicated in promoting hepatic synthesis of uncoupling protein-2, which is 
expressed in the liver of patients with nonalcoholic fatty liver disease. 
           Increased intrahepatic levels of fatty acids provide a source of 
oxidative stress, which may in large part, be responsible for the progression 
from steatosis to steatohepatitis to cirrhosis. Mitochondria are the main 
cellular source of reactive oxygen species, which may trigger steatohepatitis 
and fibrosis by three main mechanisms; lipid peroxidation, cytokine 
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induction, and induction of Fas ligand. Patients with steatohepatitis have 
ultrastructutal mitochondrial lesions; including linear crystalline inclusions 
in megamitochondria.46 This mitochondrial injury is absent in most patients 
with simple steatosis and in healthy subjects. Patients with steatohepatitis 
slowly resynthesize ATP in vivo after a fructose challenge, which causes 
acute hepatic ATP depletion.47 This impaired ATP recovery may reflect the 
mitochondrial injury found in patients with steatohepatitis.46 
         Thus, although symptoms of liver disease rarely develops in patients 
with fatty liver who are obese, have diabetes, or have hyperlipidemia, the 
steatotic liver may be vulnerable to further injury when challenged by 
additional insults. This has led to the presumption that progression from 
simple steatosis to steatohepatitis and to advanced fibrosis results from 
two distinct events.48 First, insulin resistance leads to the accumulation of 
fat within hepatocytes, and second, mitochondrial reactive oxygen species 
cause lipid peroxidation, cytokine induction, and the induction of Fas ligand.   
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DIAGNOSIS 
       The diagnosis of nonalcoholic fatty liver disease is usually suspected in 
persons with asymptomatic elevation of aminotransferase levels, radiologic 
finds of fatty liver, or unexplained persistent hepatomegaly. The clinical 
diagnosis and liver tests have a poor predictive value with respect to 
histologic involvement.49 Imaging studies, although of help in determining 
the presence and amount of fatty infiltration of the liver, cannot be used to 
accurately determine the severity of liver damage. 
     Liver biopsy is considered as best method for the detection of hepatic 
steatosis and it can also detect steatohepatitis. 
     The diagnosis of nonalcoholic fatty liver disease requires the exclusion of 
alcohol abuse as the cause of liver disease; a daily intake as low as 20 gm in 
females and 30 gm in males may be sufficient to cause alcohol-induced liver 
disease in some patients (350 ml [12 oz] of beer, 120 ml [ 4 oz] of wine, and 
45 ml [1.5 oz] of hard liquor each contain 10 gm of alcohol).50 Other causes, 
such as viruses, autoimmune responses, metabolic or hereditary factors, and 
drugs or toxins, should be ruled out. The decision on how extensive the 
serologic workup should  be individualized. 
      Even though liver biopsy is considered to be the best, some advocate that 
there are several drawbacks in using liver biopsy for this purpose. This 
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procedure is invasive, costly, and prone to complications, some minor, such 
as pain, others more severe with a recorded risk of death of 0.01%. Notably, 
just as is the case in other chronic liver disease, there is considerable 
sampling variability (40% for fibrosis staging), and a high intra and inter-
pathologist variability.51 Most importantly, the number of patients at risk for 
NAFLD is high enough that liver biopsy is not a practical and efficient tool 
for identifying those at risk of advanced fibrosis. Indeed an estimated 15-
20% of the Western European population has steatosis while more than half 
of Americans are overweight of obese. 
        So the diagnostic workup needs to be individualized and decisions 
taken accordingly. 
       Some newer methods are now emerging for the diagnosis of hepatic 
steatosis and steatohepatitis such as the H magnetic resonance spectroscopy 
and the fibrosure test for the detection of fibrosis. These tests may in course 
of time serve as a better noninvasive method for the detection of NAFLD 
 
NATURAL HISTORY 
            The natural history of nonalcoholic fatty liver disease is not well 
defined, but it seems to be determined by the severity of histological 
damage. In five series, 54 of 257 patients with nonalcoholic fatty liver 
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disease underwent liver biopsy during an average follow-up of 3.5 to 11 
years.4, 5 Of these patients, 28 percent had progression of liver damage, 59 
percent had essentially no change, and 13 percent had improvement or 
resolution of liver injury. Progression from steatosis to steatohepatitis and to 
more advanced fibrosis4, 5 or cirrhosis4, 5 has been recognized in several 
cases. Some of the few deaths occurred among the 257 patients were liver-
related, including one from hepatocellular cancer. Thus, many patients with 
nonalcoholic fatty liver disease have a relatively benign course, whereas in 
some others, the disease progresses to cirrhosis and its complications. 
       Patients found to have pure steatosis on liver biopsy seem to have the 
best prognosis within the spectrum of nonalcoholic fatty liver disease, 
whereas features of steatohepatitis of more advanced fibrosis are associated 
with a worse prognosis. In one study, 52 progression of liver fibrosis occurred 
only in patients with necrosis and inflammatory infiltration on liver biopsy. 
In another study, 36 percent of patients with nonalcoholic fatty liver disease 
died after a mean follow-up of 8.3 years, liver-related diseases were the 
second most common cause of death, exceeded only by cancer. Some data 
suggest that the coexistence of steatosis with other liver diseases, such as 
hepatitis C virus infection, could increase the risk of progression of the liver 
disease.53 The natural history of cirrhosis resulting from nonalcoholic fatty 
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liver disease has not been completely defined. In a recent study, 54 only 2.9 
percent of 545 liver-transplantation procedures performed in a single center 
were for end-stage steatohepatitis. 
        This suggests that although nonalcoholic fatty liver disease is common, 
only a minority of patients will require liver transplantation.  
TREATMENT 
 Many clinical trials on to find out an effective method of treatment of 
Nonalcoholic Fatty Liver Disease, many treatment options have been 
suggested and they are: 
1. Treatment of associated disorders 
        Gradual weight loss, Control of diabetes, Control of dyslipidemia 
2. Potential pharmacological approaches 
        Improved insulin resistance 
   Metformin, Thiazolinediones: Pioglitazone 
        Improved dyslipidemia 
 Clofibrate, Gemfibrozil, Atorvastatin, Probucol 
        Antioxidants 
Tocopherol, Tocopherol/ Ascorbic acid, Betaine, Ursodeoxycholic acid, 
S-adnosyl methionine. 
3. Liver transplantation 
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MATERIALS AND METHODS 
INCLUSION CRITERIA 
Patients who were diagnosed to have Type 2 Diabetes Mellitus, for more 
than 3 years duration, belonging to both sexes and with age of more than 40 
years attending Diabetology Out-patient Department of Stanley Medical 
College were included in the study. 
 
EXCLUSION CRITERIA 
Patients with history of alcohol consumption for any duration of time were 
excluded. 
Persons with previous history of jaundice, ascites and signs of liver cell 
failure were excluded. 
Persons who tested positive for Hepatitis B serology by Elisa or by card test 
were excluded. 
Patients with history of intake of Methotrexate, Amiodarone, 
Glucocorticoids, Synthetic Estrogens, Nucleoside Analogues (ddI, AZI) 
were excluded. 
Persons with history of major abdominal surgeries were excluded. 
Persons with history of Chronic Renal Failure and severe Ischemic Heart 
Disease were excluded from the study. 
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Patients with history of Ketoacidosis  or with a history of prolonged 
treatment with insulin were excluded. 
 
The Study Population was derived from the patients attending the 
Diabetology Outpatient Department of Stanley Medical College from 
January 2007 to August 2008. 
A detailed history was taken regarding the Duration of Diabetes, Symptoms 
pertaining to the Hepatobiliary System. 
History of medications was obtained in detail. 
History of alcohol consumption was recorded and any person with history of 
alcohol use was excluded from the study population. Any history of previous 
abdominal surgeries such as Jejuno- Ileal Bypass, Gastrectomy was 
recorded. 
Women were enquired about oral contraceptive or hormonal use. 
A detailed Clinical Examination of all systems was made and signs of Liver 
Cell Failure, Organomegaly, Ascites were looked for.  
The patient’s Height & Weight were recorded & Body Mass Index was 
calculated. 
BMI is defined as weight in kilograms divided by height in meter’s squared. 
Patients were classified according to BMI as follows: 
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Underweight: BMI <18.5 kg/m2 
Normal weight: BMI 18.5 to 24.9 kg/m2 
Overweight: BMI 25 to 29.9 kg/m2 
Obese: BMI >30 kg/m2 
Blood pressure measurements were taken.  
THE LABORATORY INVESTIGATIONS DONE INCLUDED. 
 A Complete Blood  Count. 
Urine for Albumin, Sugar and Deposits. 
Blood sugar: Random, Fasting & Post-Prandial. 
Blood Urea and Serum Creatinine. 
Serum Electrolytes – Sodium & Potassium. 
LIVER FUNCTION TESTS 
   SGOT  (Normal value 5 to 35 IU/L) 
   SGPT (Normal value 5 to 35 IU/L) 
   Serum Alkaline Phosphatase (Normal value 60 to 170 IU/L) 
   Serum Total Bilirubin (Normal value < 1 mg/dl) 
   Serum Total Proteins. 
FASTING LIPID PROFILE 
The fasting lipid profile was done after a minimum of 12 hours of overnight 
fasting and the following tests were done. 
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Serum Total Cholesterol. 
Serum Triglycerides (TGL). 
Serum High Density Lipoprotein (HDL) 
Serum Low Density Lipoprotein (LDL) was calculated using the Friedwald 
formula: 
LDL-C  =  Total Cholesterol – HDL C – (Triglyceride/5). 
Ultrasonogram of Abdomen was done with particular focus on the liver. 
The presence of diabetes was defined according to the WHO CRITERIA 
AS: 
     Symptoms of diabetes, plus Random Blood concentration more than 200 
mg/dl. 
     Fasting plasma glucose more than 126 mg/dl. (Fasting is defined as no 
caloric intake for at least 8 hours) 
      Two-hour plasma glucose more than 200 mg/dl during an oral Glucose 
Tolerance Test. (This test should be done using a glucose load containing the 
equivalent of 75 gm of anhydrous glucose dissolved in water). 
Type 2 DM subjects were defined as those with previous physician-
diagnosed diabetes in whom hyperglycemia had been controlled for one year 
or more with oral hypoglycemic agents and diet, with absence of history of 
ketoacidosis initially, or during the course of the disease.55 
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IMAGING STUDY 
Steatosis was defined as the presence of an Ultrasonographic pattern 
consistent with “BRIGHT LIVER,” with evident Ultrasonographic contrast 
between hepatic and renal parenchyma, vessel blurring, focal sparing, and 
narrowing of the lumen of the hepatic veins, according to international 
guidelines.31 The upper limit of normal liver size was 15 cm in the 
longitudinal plane, any measurement above this was considered 
hepatomegaly. Mild hepatomegaly was defined as liver size > 15 – 18 cm in 
the longitudinal plane. 
The presence of steatosis was graded from mild to severe and for calculation 
purposes all grades were taken as positive fatty liver. 
All the images were reviewed by another radiologist to minimize observer 
errors. 
The L&T Ultrasound machine used had a 3.5 MHz probe. 
STATISTICAL ANALYSIS 
Statistical analysis of the data obtained from the study was done using the 
‘z’ test or ‘normal’ test to compare the mean values of two groups of 
participants. The chi-square test was used to compare the prevalence 
between the two groups. The calculations were done for 5% level of 
significance. ( P = 0.05).     
 40
 
 
 
 
 
 
 
 
 
 
RESULTS AND 
OBSERVATIONS
 41
RESULTS AND OBSERVATIONS 
     A total of 109 patients diagnosed with type 2 Diabetes Mellitus for 3 
years and more were included in this study after applying the selection 
criteria. Most of them belonged to the low and middle socio-economic 
groups. 
     Out of the 109 participants 60 were females and 49 were males. 
SEX DISTRIBUTION 
TOTAL
MALES
FEMALES
 
     The age of the participants varied from 40 to 75 years and the mean age 
was 52.45 ± 7.15 years. 
Out of the total 109 participants 53 persons ( 48.62 %) had 
ultrasonographically detected fatty liver. Most of them had moderate or 
severe steatosis ultrasonogram wise. They were called as the NAFLD (Non 
Alcoholic Fatty Liver Disease) group. Of these 53 persons 36 were females 
and 17 were males. 
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SEX-WISE PREVALENCE 
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 Female(total 60) Male (total 59) P value 
NAFLD in USG(53) 36 (60 %) 17 (34.69 %) < 0.05 
Normal USG(56) 24 (40 %) 32 (65.31 %)  
 
 
 
    The duration of Diabetes varies from 3 to 20 years in the study group with 
a mean value of 5.48 ± 3.57 years. 
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     The mean duration of Diabetes in the fatty liver group was 5.47 ± 3.19 
years as compared to 5.48 ± 3.94 years in the normal liver group. There was 
no significant difference between the NAFLD group and the normal group 
duration wise (P value >0.05). 
    The age wise distribution of patients with and without fatty liver in 
Ultrasonogram is as follows. 
Age group Total(109) NAFLD(53) Normal(56) 
40-49 years 40             16 (30.1 %) 24 (42.8 %) 
50-59 years 49 26 (49.05 %) 23 (41.07 %) 
>60 years 20 11 (20.75 %) 9 (16.98 %) 
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CLINICAL FEATURES 
     Most of the persons with fatty liver were asymptomatic, i.e. 28 out of 
total 53. The next common symptom was right upper quadrant discomfort, 
which was present in 11 out of 53 patients, 2 persons in the fatty liver group 
had complaint of abdominal distension, and no patient had the complaint of 
jaundice, 16 persons had a feeling of generalized weakness and malaise. 
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      Clinical examination of abdomen revealed hepatomegaly in 6 patients 
with fatty liver and 1 patient in the normal group. No patient in both groups 
had splenomegaly or ascites. Ultrasonography showed hepatomegaly in 9 
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out of 53 persons with fatty liver compared to 1 out of 56 persons in the 
normal liver group. 
 
BODY MASS INDEX 
 
          The Body Mass Index varied (BMI) from 17 to 37 kg/m2 with a mean 
Body Mass Index of 23.60 ± 3.17 kg/m2. A BMI of 25 kg/m2 was taken as a 
cut-off between overweight and obese, 71 persons had a BMI below 25 kg/ 
m2 and 38 persons had a BMI of above 25 kg/m2. Only 4 persons had a BMI 
of more than 30 kg/m2  and all of them had fatty liver. Out of the patients 
with a BMI of more than 25 kg/m2    (total 38) 30 persons had fatty liver 
detected in ultrasonogram. In the low BMI group (total 71) 27 persons had 
Ultrasonographically detected fatty liver. 
Mean BMI values: 
NAFLD group Normal group P value 
24.97 ± 3.54 kg/ m2 22.29 ± 2.05 kg/ m2 < 0.05 
 
 
BMI (kg/ m2) NAFLD GROUP (53) NORMAL USG (56) 
<25 (71) 23 (32.39 %)) 48 (67.61 %) 
>25 (38) 30 (78.94 %) 8 (21.06 %) 
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LABORATORY INVESTIGATIONS 
BLOOD SUGAR 
       All the patients had a random, fasting and postprandial blood sugar 
estimation done. 
       The number of patients with and without fatty liver in the different 
fasting blood sugar categories was as follows. 
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FBS (mg/dl) TOTAL FATTY LIVER NORMAL USG 
< 125 19 6 13 
125 TO 150 38 20 18 
150 TO 175 30 15 15 
> 175 22 12 10 
 
FASTING BLOOD SUGAR WISE DISTRIBUTION 
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 The mean fasting blood sugar in the above two categories are: 
NAFLD group Normal group P value 
156.19 ± 36.53 mg/dl 146.67 ± 32.38 mg/dl > 0.05 
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LIVER FUNCTION TESTS 
    The liver function tests done included the Serum Trasnsaminases, Serum 
Alkaline Phosphatase, Serum Total Bilirubin and Total Proteins. 
    The normal value of serum transaminases is 5 to 35 IU/l.  The normal 
value of Serum alkaline Phosphatase is up to 150 IU/l. The participants were 
categorized into a low Transaminase level group of 25 IU/l or below and a 
high normal and increased Transaminase level group with a value of more 
than 25 IU/l. 
 
 
SGOT LEVELS: 
SGOT levels Total (109) NAFLD group 
(53) 
Normal group 
(56) 
< 25 IU/l 83 38 (71.69 %) 45 (80.35 %) 
25-35 IU/l 16 8 (15.09 %) 8 (14.28 %) 
> 35 IU/l 10 7 (13.20 %) 3 (7.14 %) 
 
 
Mean SGOT values: 
 
NAFLD group Normal group P value 
25.02 ± 20.64 IU/l 18.41 ± 11.97 IU/l < 0.05 
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SGPT 
     Out of the total of 53 persons who had Ultrasongraphically proven fatty 
liver 26 persons had an SGPT value of more than 25 IU/L and 11 had an 
SGPT value of more than 35 IU/L. 
     Out of 56 persons who had normal liver in Ultrasonography 11 persons 
had an SGPT value of more than 25 IU/L and 3 persons had an SGPT value 
of more than 35 IU/L. 
Mean SGPT Values: 
NAFLD group Normal group  P value 
29 ± 28.35 IU/L 17.47 ± 10.02 IU/L < 0.05 
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ALKALINE PHOSPHATASE 
     Out of the total of 53 persons who had Ultrasonographically proven fatty 
liver 19 (35.84%) persons had a Serum Alkaline Phosphatase value of more 
than 150 IU/L and 4 individuals had a value of more than 250 IU/l. 
    Out of a total of 56 persons who had normal liver in Ultrasonography 17 
(30.35%) persons had a Serum Alkaline Phosphatase value of more than 150 
and 1 person had a Serum Alkaline Phosphatase value of more than 250 
IU/l. 
Mean Alkaline Phosphatase Values: 
NAFLD group Normal group P value 
123.97 ± 66.13 IU/L 106.52 ± 68.75 IU/L > 0.05 
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SERUM BILIRUBIN: 
       The mean Serum Total Bilirubin in the NAFLD group was 1.10 mg/dl 
and the Serum Total Bilirubin in the normal group was 0.84 mg/dl. There 
was no statistically difference in levels of Serum Bilirubin between the two 
groups. 
TOTAL PROTEINS: 
      The mean value of Total Protein in the NAFLD group was 6.43 gm and 
in the normal group it was 6.48 gm. There was no statistically difference in 
levels of Total Protein between the NAFLD and normal liver groups. 
FASTING LIPID PROFILE 
      The lipid done after an overnight fasting of 12 hours included Total 
Cholesterol, Serum Triglycerides (TGL), Serum High Density Lipoprotein 
(HDL) and the Low Density Lipoprotein (LDL) value was calculated using 
the Friedwald formula. 
       According to the ATP III guidelines for the treatment of lipid disorders, 
the levels of lipoproteins were considered abnormal if total cholesterol was 
above 200, if serum triglyceride level was above 150 mg/dl, serum HDL 
level was below 50 and LDL levels were above 100. 
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TOTAL CHOLESTEROL: 
       A total of 58 out of 109 had a high Total Cholesterol value. Among the 
NAFLD group out of the total 53 patients 37 (69.81 %) had a Total 
Cholesterol value of more than 200 and among the normal liver group 21 
(37.5 %) out of the 56 had a Total Cholesterol value of more than 200. 
The mean total cholesterol values are as follows: 
NAFLD group Normal group P value
225.33 ± 43.95 mg/dl 192.67 ± 35.58 mg/dl < 0.05 
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TRIGLYCERIDES: 
     Out of the 53 patients in the NAFLD  group 31 (58.49 %) patients had a 
triglyceride level of more than 150 mg/dl . Of the 56 patients in the normal 
liver group 23 (41.07 %) persons had a triglyceride level of more than 150 
mg/dl. 
The mean triglyceride levels: 
NAFLD group Normal group  P value 
235.82 ± 105.18 mg/dl 155.81 ± 61.08 mg/dl < 0.05 
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HDL 
     Out of the 53 patients in the NAFLD group 30 (56.6 %) patients had a 
HDL level of less than 50 mg/dl. Of the 56 patients in the normal liver group 
23 persons had a HDL level of less than 50 mg/dl. 
The mean HDL levels: 
NAFLE group Normal group P value 
46.24 ± 8.03 mg/dl 49.21 ± 9.93 mg/dl > 0.05 
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MEAN HDL VALUES: 
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LDL 
     The LDL levels varied from 52 to 273 mg/dl and a total of 74 patients 
had LDL levels above 100 mg/dl. In the fatty liver group 39 out of the 53 
persons had elevated LDL values above 100 mg/dl. In the normal liver group 
35 out of the 66 persons had an elevated LDL level of more than 100 mg/dl. 
MEAN LDL VALUES: 
NAFLD group Normal group P value
128.52 ± 41.66 mg/dl 111.45 ± 27.80 mg/dl < 0.05 
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ABSTRACT OF STATISTICAL ANALYSIS 
MEAN VALUES: 
PARAMETER NAFLD 
GROUP 
(n=63) 
NORMAL 
USG GROUP 
(n=66) 
STATISTICAL 
SIGNIFICANCE 
AT 5% LEVEL 
DURATION OF 
DIABETES (yrs) 
5.57 ± 3.19 5.48 ± 3.94 No significant 
difference (P 
value=0.05) 
BMI (kg/m2) 24.97 ± 3.54 2.29 ± 2.05 Significant 
difference present 
(P value<0.05) 
SGOT (IU/L) 25.02 ± 20.64 18.41 ± 11.97 Significant 
difference present 
(P value<0.05) 
SGPT (IU/L) 29.00 ± 28.35 17.47 ± 10.02 Significant 
difference present 
(P value<0.05) 
ALP (IU/L) 123.97 ± 66.13 106.52 ± 68.75 No significant 
difference (P 
value=0.05) 
BILIRUBIN 
(mg/dl) 
1.10 ± 1.12 0.84 ± 0.36 No significant 
difference (P 
value=0.05) 
TOTAL 
CHOLESTEROL 
(mg/dl) 
225.33 ± 43.95 192.67 ± 35.38 Significant 
difference present 
(P value<0.05 
TGL (mg/dl) 235.82 ± 105.18 155.81 ± 61.08 Significant 
difference present 
(P value<0.05 
HDL (mg/dl) 46.24 ± 8.03 49.21 ± 9.93 No significant 
difference (P 
value=0.05) 
LDL (mg/dl) 125.82 ± 11.66 111.45 ± 27.80 Significant 
difference present 
(P value<0.05 
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ABSTRACT OF DATA:    LIVER ENZYMES : 
ENZYME 
LEVEL(IU/L) 
NAFLD GROUP 
(53) 
NORMAL  USG 
(56) 
P 
VALUE 
SGOT < 25 (83) 38 45 > 0.05 
             >25 (26) 15 11  
SGPT < 25 (58) 16 42 < 0.05 
           > 25 (51) 37 14  
ALP < 150 (68) 30 38 > 0.05 
        > 150 (41) 23 18  
 
LIPID PROFILE: 
PARAMETER 
(mg/dl) 
NAFLD GROUP 
(53) 
NORMAL USG 
(56) 
P VALUE 
TC     < 200 (51) 16 35 <0.05 
          > 200 (58) 37 21  
TGL  < 150 (55) 22 33 <0.05 
          > 150 (54) 31 23  
HDL  < 50  (53) 30 23 >0.05 
          > 50  (56) 23 33  
LDL  < 100 (35) 14 21 > 0.05 
          > 100 (14) 39 35  
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Statistically significant difference at 5 % level (P=0.05) between NAFLD 
and NORMAL USG groups was present for SGPT,  Total Cholesterol and 
Triglyceride levels. Other parameters did not show any significant difference 
by comparing the two groups using ‘chi square test’. But mean LDL levels 
in the NAFLD group were much higher than in that of the normal group.  
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DISCUSSION 
       A total of 109 patients were included in this study after applying the 
selection criteria. 
       Out of the 109 type 2 diabetics included in this study 60 were females 
and 49 were males, the number of males was lesser than females because 
alcohol intake was taken as exclusion criteria and so many males got 
excluded. 
     Of the 109 diabetics included in this study 53 (48.6 %) of them had 
ultrasonographically detectable fatty liver, according to several reports the 
prevalence of fatty liver in Diabetes Mellitus is more than that of the general 
population, many studies have shown that the prevalence of NAFLD in type 
2 Diabetes Mellitus was upto 70 %. 
The study of fatty liver in type 2 Diabetes Mellitus 
Series  Prevalence of NAFLD by USG (%) 
Present ( n=109 ) 48.6 % 
Daad H Akbar (n-119)55 55% 
Gupte P et al (n=100)56 49% 
    
The prevalence of fatty liver in this study group is similar to the prevalence 
observed in other studies. 
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       Out of the 60 female type 2 diabetics 35 (58.33 %) had fatty liver 
detected by ultrasonography and out of the 49 male type 2 diabetics 17 
(34.69 %) had fatty liver. In this study female sex had a higher prevalence of 
fatty liver (M : F ratio is 1:1.57). 
     Many studies have shown that female sex has a higher predisposition to 
the development of fatty liver in the general population. In other studies 
conducted among type 2 diabetics the prevalence was found to be more 
among females. 
     There was no significant variation in the mean age between the NAFLD 
group and the normal liver group. The mean age of the study population was 
higher because only persons above the age of 40 years were recruited into 
the study. 
DURATION OF DIABETES: 
      The mean duration of Diabetes in persons with NAFLD was 5.47 ± 3.19 
years and the mean duration of Diabetes in persons with Normal liver in 
USG was 5.47 ± 3.94 years. 
       No statistically significant relationship was found between the presence 
of NAFLD and the duration od Diabetes. The result were similar to the study 
conducted in Saudi Arabia (Daad H Akbar et al ).55 
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        BODY MASS INDEX :  The mean Body Mass Index in the NAFLD 
group was significantly higher than that of the normal group. 38 persons had 
a BMI of more than 25 kg/m2 and out of them 30 (78.94 %) had NAFLD. 
In the study done by Daad H Akbar et al in Saudi Arabia, Obesity was 
identified as an independent factor for the development of NAFLD.55 
    The number of persons with a BMI of more than 30 kg/m2 was less 
compared to studies done in other countries. This is probably due to the low 
and middle socioeconomic status of the study group. In our study group too 
the persons with high BMI had prevalence of fatty liver equal to that 
observed elsewhere. 
CLINICAL SYMPTOMS: 
    Following are the clinical symptoms observed in the group with NAFLD 
compared to other studies: 
Symptoms and signs Present series 
(n=53) 
 
Saudi series55 
(n=64)  
Virginia series56 
(n=75) 
Asymptomatic 52.8 % 80 % 60% 
Fatigue 30.1  % NA 30 % 
Right upper quadrant 
discomfort 
20.75 % 17 % 30 % 
Jaundice 0 % NA NA 
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  Our study had a slight but statistically no significant variation in the 
incidence of symptoms. 
  The natural history of NASH in Australia was followed in 42 patients for 
upto 21 years.5 Upper abdominal pain was a common reason for 
presentation. Many studies have shown a high proportion of patients (48 % 
to 100 %) have no symptoms of liver disease, and a small percentage 
(especially children56 ) have vague abdominal discomfort or pain in the right 
upper quadrant56 or fatigue and malaise.  
 
HEPATOMEGALY: 
     On clinical examination and Ultrasonogram wise 9 patients (16.18 %) out 
of 53 in NAFLD group had hepatomegaly. The incidence of hepatomegaly 
in different studies in diabetes is as follows. 
Series No of patients (%) 
Saudi series (2003)55 56 out of 64 (88%) 
Virginia series (1996)24 16 out of 76 (22%) 
Vaishnave series (1970) 28 out of 113 (24.7%)
Lal et al (1971) 10 out of 25 (40%) 
Present series 9 out of 53 (19%) 
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There were gross variations in the incidence of hepatomegaly between many 
groups. None of the patients in the NAFLD group had splenomegaly of 
ascites. Many studies have shown that the most common finding at initial 
presentation is asymptomatic hepatomegaly.4, 5 
LABORATORY INVESTIGATIONS: 
    The prevalence of NAFLD was not significantly different among different 
levels of fasting sugar levels in our study. 
     Many studies have shown that the levels of blood sugar did not have any 
correlation with development of NAFLD. Moreover HbA1c estimation was 
done in the Saudi study, 55 and there was no significant relationship between 
glycemic control and NAFLD. 
TRANSAMINASES AND ALKALINE PHOSPHATASE: 
     There was no statistical difference between the two groups in terms of 
SGOT and Alkaline Phosphatase elevation in terms of number of persons 
showing enzyme elevation. But when the mean enzyme values were 
compared the NAFLD group had a statistically significant higher value than 
the normal group. 
     Asymptomatic elevation of transaminases is one of the commonest 
reported and studied abnormality in NAFLD. The most frequently noted 
abnormality is two to threefold elevation of levels of ALT and AST in 
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plasma.4, 5 V Ness and Diehl49 found that 19 % of patients (17 of 90) who 
had liver biopsy for evaluation of chronically elevated plasma levels of ALT 
and AST in contrast to 7% to 9% of all patients who had liver biopsies for 
other reasons, nonalcoholic steatosis or steatonecrosis. 
     Alkaline phosphatase levels are abnormal in fewer than half of patients.4 
Another article has stated that Liver transaminases may be normal, or only 
marginally elevated (Mofrad et al, 2003).57 There is poor correlation 
between biochemistry, ultrasonography and histology, and the entire 
histological spectrum of NAFLD can be seen in individuals with normal 
transaminase values (Mofrad et al, 2003).57 
     Some studies have mentioned that Liver enzyme levels in NAFLD  
patients fluctuate, normal values being present in up to 78% of patients at 
any one time. When levels are elevated, the increase is mild and often 
restricted to one or both of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST). The AST:ALT ratio is usually less than 1, although 
it may reverse in the presence of cirrhosis. 
    The SGOT:SGPT ratio in the NAFLD group in this study was 0.8. 
    In cases with NAFLD the SGOT : SGPT ratio is less than 1 according to 
literature. In two major studies, 5 levels of ALT were noted to be higher than 
levels of AST, a pattern that contrasts with that seen in alcoholic hepatitis. 
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Although values < 1 suggest NAFLD, a ratio of ≥2 is strongly suggestive of 
alcoholic liver disease. 
     There was no statistically significant difference in the levels of bilirubin 
and total proteins between the two groups which were similar to the 
observations done elsewhere. 
FASTING LIPID PROFILE: 
   Traditionally Total Cholesterol and Triglyceride values were found to be 
elevated in persons with NAFLD. Our study population consisted of type 2 
diabetics and atherogenic dyslipidemias are common among diabetics. 
    The  total Cholesterol, TGL values were significantly higher in terms of 
number of persons showing elevation and also in terms of the mean values in 
the NAFLD group. The number of persons showing elevated LDL was 
similar in both groups but the mean LDL was much higher in the NAFLD 
group. 
Type of Lipid % of persons Mean value (mg/dl)
Increased TC 69.8 % 225.3 ± 43.95 
Increased TGL 49.5 %  235.82 ± 105.18 
Increased LDL 60.6 % 128.52 ± 8.03 
Decreased HDL 71.4 % 46.54 ± 41.66 
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The HDL values were similar in both groups with mean values being 
marginally lower in the NAFLD group. 
     The values observed in other studies were as follows. Hyperlipidemis 
(hypertriglyceridemia, hypercholesterolemia, or both) is another common 
abnormality and has been reported in 20% to 81% of patients with 
NAFLD.2,4,5 Dyslipidemia was present in 65% of cases of NAFLD at the 
Virginia NAFLD clinic.24 In another study, Hypertriglyceridemia and fatty 
liver: clinical diagnosis of fatty liver and lipoprotein profiles in 
hypertriglyceridemic patients with fatty liver. Most of these patients with 
fatty liver had hypertriglyceridemia. 
    Ongoing research has shown that Non alcoholic fatty liver disease has a 
broad clinical spectrum, different presentations, most of the research has 
shown that NAFLD has a stable course, some subsets of the NAFLD 
population might have a progression to severe forms of disease with 
inflammation termed steatohepatitis and a minority may end up in having 
cirrhosis. A significant proportion of patients previously thought to have 
cryptogenic cirrhosis share many of the clinical and demographic 
features of NAFLD, suggesting that the etiology of their cirrhosis may 
be unrecognized NAFLD. (Powell et al.1990 et al, 19905; Cadwell23 et al, 
1999, Poonawala et al, 2000). Outcomes of NAFLD are different among 
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different groups and other studies that looked at the outcome of people with 
NAFLD and Diabetes also report a more aggressive form of disease and 
higher overall mortality and mortality related to liver disease (Sargin et al, 
2003). Older age, increasing obesity, type 2 Diabetes and 
hypertriglyceridemia appear to be the strongest independent predictors of 
more advanced disease (Angulo et al, 1999, Dixon et al, 2001). 
      Follow up of patients with NAFLD has been discussed and monitoring 
patients with NAFLD is difficult because liver enzyme level tend to improve 
regardless of whether liver fibrosis worsens or improves.60 In addition, it 
may take several decades of monitoring before the development of 
complications is observed. Therefore, follow-up should be focused on 
patients who have risk factors for advanced disease.   
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LIMITATIONS OF THIS STUDY 
   Although Ultrasound was sensitive for the detection of steatosis its 
accuracy was greater if more than 30 % of the liver was affected by 
steatosis. This might lead to an under-estimation of prevalence. But several 
studies have been conducted with Sonography alone and our study was 
based on those lines. 
     Since our study population was derived from the patients attending 
outpatient clinic, liver biopsy was not feasible and most of the patients were 
not willing for invasive procedures or inpatient stay. Hence liver biopsy was 
not carried out. As in all imaging procedures observer error is expected and 
we tried to minimize this error by review of images by another radiologist. 
    Moreover certain investigations like insulin levels, C-peptide levels, 
HbA1c, Transferrin saturation and ferritin levels could not be done in our 
setup. So we were unable to document hyperinsulinemia etc. 
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CONCLUSIONS 
1. Non alcoholic fatty liver disease is common among the type 2 diabetic 
population of this region. (Prevalence 48.6% of type 2 diabetics). 
2. Female sex has a significantly higher prevalence of non alcoholic fatty 
liver disease as observed in other geographical regions. ( M: F ratio is 
1: 1.57). 
3. The persons with a higher body mass index are at a greater risk of 
developing non alcoholic fatty liver disease ( 78.94 % diabetics with a 
BMI > 25 kg/m2 had ultrasonographically proven fatty liver) 
4. Most of the patients of non alcoholic fatty liver disease are 
asymptomatic (52.8%). Right Upper Quadrant discomfort and malaise 
are other symptoms. 
5. Hepatomegaly was the commonest physical finding in Non alcoholic 
fatty liver disease (16.98%). It was found to be present in varying 
incidences in other studies. 
6. No significant relationship was observed between the age of patient, 
duration of diabetes, fasting blood sugar levels and the presence of 
Non alcoholic fatty liver disease by ultrasound. 
7. There was a significant difference in mean serum transaminase 
(SGOT, SGPT) levels between the normal and fatty liver groups with 
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the fatty liver group having higher values. But absolute elevation of 
transaminases above normal was not seen in many cases. 
8. There was no significant relationship observed between Serum Alkalin 
Phosphatase, Total Bilirubin and Total Proteins and the prevalence of 
fatty liver by ultrasound. 
9. Significantly high Serum Total Cholesterol, Triglycerides and Low 
Density Lipoproteins were present in persons with fatty liver. 
10. No significant correlation was observed between Low Density 
Lipoprotein levels and the presence of fatty liver in Ultrasound but 
marginally low mean HDL values were present in the fatty liver group. 
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